



STATE OF CONNECTICUT
INSURANCE DEPARTMENT

BULLETIN HC - 79

June 17, 2010

TO: All Health Insurers and Health Care Centers Authorized To Conduct Business In Connecticut

RE: Revised Pre-Authorization Form for Cancer Clinical Trials

This is a reminder to all health insurers and health care centers operating in Connecticut that pursuant to sections 38a-504f and 38a-542f of the Connecticut General Statutes, and section 38a-504a-3 of the Regulations of the Connecticut State Agencies, all requests for coverage of routine patient care costs for individuals enrolled in Phase I, II and III cancer clinical trials must be pre-authorized through a submission of a completed, standardized form that all providers, hospitals and institutions shall submit when seeking to enroll an insured person in the cancer clinical trial. The Connecticut Insurance Department ("Department") wants to make sure that the form is properly required and used to enable proper identification of cancer clinical trial participants and proper data collection related to benefits provided under the cancer clinical trial mandates.

Working with representatives of the Connecticut Association of Health Plans, medical directors and counsel of licensed health care centers, the Attorney General's Office and clinical trial staff of the Neag Comprehensive Cancer Center of the University of Connecticut, the Department undertook a review of the cancer clinical trial pre-authorization form to update it. As a result of that review, the form has been revised and a copy of the revised form is attached for your information. A copy of the form is also available on the Department's website under "Forms".

Please contact the Insurance Department Life & Health Division at cid.lh@ct.gov with any questions.

Thomas R. Sullivan
Insurance Commissioner

**Request For Authorization for Coverage of Routine Patient Care Costs
Associated with Cancer Clinical Trials**

Section I

Date: _____

Member name: _____

Member ID #: _____

Member Date of Birth: _____

Health Insurer: _____

Treating Physician: _____

Contact Person for Additional Information Regarding Member's Treatment:

Name: _____

Address: _____

Phone number: _____

Fax number: _____

E-mail address: _____

Service requested is: ___ Outpatient ___ Inpatient ___ Office Setting

If outpatient or inpatient is checked:

Facility name & address: _____

Please Note: Pursuant to Connecticut General Statutes Sections 38a-504a *et seq.* (individual coverage) or 38a-542a *et seq.* (group coverage), you may be asked to provide additional information about the cancer clinical trial or the member's diagnosis and condition prior to the authorization of this request.

Member name: _____ Member ID#: _____

Section II

Diagnosis code: _____ Stage _____

Clinical trial phase: ___ I ___ II ___ III

Clinical trial sponsor: _____

Please identify the funding source for the trial? (federal government, private entity, charitable organization – please provide specific entity name) _____

Clinical Trial has been reviewed and approved by: *(must check one per Conn. Gen. Stat. Sec. 38a-504b or 38a-542)*

- ___ National Institute of Health
- ___ National Cancer Institute
- ___ Federal Food and Drug Administration
- ___ Federal Dept. of Defense
- ___ Federal Dept. of Veterans Affairs

Check one: ___ Single center study ___ Multiple center study

List name(s) and address(es) of center(s):

Information regarding the proposed trial: (if additional space is needed for any of the following questions, please attach separate sheet)

1. Please state the anticipated therapeutic effect _____

2. How does the protocol differ from the standard treatment for this diagnosis?

3. Please provide a list of tests, procedures, drugs, equipment and other services to be covered by the trial.

4. Please attach copies of the study calendar and schema page from the clinical trial proposal.